Navigation Links
Off-Label Stent Use: How Important Are FDA Approvals to Physicians?

Millennium Research Group survey finds that physicians place importance on

indication-specific FDA approval

WALTHAM, Mass., April 2, 2008 /PRNewswire/ -- Given the recent investigation by the US Department of Justice into the marketing of biliary stents for off-label uses in the peripheral vasculature, obtaining FDA approval for device use in specific arteries could become a key focus for stent manufacturers. A recent study conducted by Millennium Research Group at the Society of Interventional Radiology 33rd Annual Scientific Meeting in Washington, DC found that a significant portion of surveyed physicians would increase their use of biliary stents if the device received FDA approval for use in the peripheral vasculature; some physicians said their use could increase by as much as 50%.

Although stents on the market are only approved for use in the bile ducts, these stents have larger diameters than those used in coronary arteries, making them an attractive choice for physicians to use the peripheral arteries, such as the iliac artery. Once a stent has received pre-market approval from the FDA, physicians are free to use the stent off-label anywhere in the body; however, manufacturers can only promote the device for the specific indication(s) for which FDA approval has been granted.

Millennium Research Group's survey gauged the importance of FDA pre-market approval in physician decisions to use a particular stent brand, and also questioned physicians on whether or not they would be willing to pay a premium for a stent with artery-specific approval.

"The ability of a manufacturer to market FDA approval for a stent in a specific indication would provide physicians with increased confidence in the device's safety and efficacy," says Darren Navarro, Senior Analyst at Millennium Research Group. "Physician attitudes toward off-label use of stents may provoke new manufacturer initiatives to obtain artery-specific FDA approval. Furthermore, it may enable manufacturers to increase the price of their stents, growing revenues."

About Millennium Research Group

Millennium Research Group (, a Decision Resources, Inc. company (, is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports, surveys, focus groups, and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent
2. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
4. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
5. Tryton Medical Receives CE Mark Approval for its Side-Branch Stent
6. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
7. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
8. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
9. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
10. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
11. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
Post Your Comments:
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/25/2015)... ANNAPOLIS, Md. , Nov. 25, 2015  PharmAthene, ... of Directors has adopted a stockholder rights plan (Rights ... its net operating loss carryforwards (NOLs) under Section 382 ... --> --> PharmAthene,s use of its ... an "ownership change" as defined in Section 382 of ...
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
Breaking Biology Technology:
(Date:11/12/2015)... -- A golden retriever that stayed healthy despite having the ... a new lead for treating this muscle-wasting disorder, report ... MIT and Harvard and the University of São Paolo ... Cell, pinpoints a protective gene that boosts muscle ... Boston Children,s lab of Lou Kunkel , PhD, ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
Breaking Biology News(10 mins):